News Releases

Date	Title	Additional Formats
November 4, 2026	Phathom Pharmaceuticals to Participate in November Investor Conferences
November 3, 2026	Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
October 29, 2026	Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
October 26, 2026	Phathom Pharmaceuticals Provides Update on FDA Litigation
October 23, 2026	Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
October 19, 2026	Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
October 12, 2026	Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
October 8, 2026	Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
September 29, 2026	Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
September 1, 2026	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences